Antibody Drugs Genome In-Vitro 
Drug Discovery World
APRIL 8, 2024
Aviv Regev, Head and Executive Vice President of Research and Early Development at Genentech, opened the session with a discussion of how advances in genomic sequencing are fostering the development of data-rich cell atlases and what that data could mean for new insights into cancer biology and novel therapeutics.
Drug Discovery World
MARCH 26, 2024
For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. OR: The presentations at ESMO TAT 2024 highlighted our advances in targeted and more personalised anti-tumour therapies. MT: What data did you present at the conference?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
OCTOBER 9, 2021
Roche (SIX RO, ROG; OTCQX RHHBY) now posted that gantenerumab, ananti-amyloid beta antibody developed for subcutaneous administration, has been granted Improvement Rectifier Designation by theU.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice).
The Pharma Data
OCTOBER 14, 2021
Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD).
Drug Discovery World
DECEMBER 8, 2023
Investments in AI and related technologies are driving this seismic shift where modest improvements in early-stage drug development success rates enabled by AI and machine learning could lead to an additional 50 novel therapies over 10 year s, a more than $50 billion opportunity.
The Pharma Data
NOVEMBER 23, 2021
Vital results from the phase I/ II GO29781 study, presented for the first time and featured in the ASH press programme, showing mosunetuzumab, a CD20xCD3 T- cell engaging bispecific antibody immunotherapy, achieved high response rates with a manageable safety profile. The safety profile was similar for Polivy plus R-CHP versus R-CHOP.1
The Pharma Data
NOVEMBER 11, 2021
”People with COVID-19 across Europe are formerly being treated with Ronapreve grounded on exigency authorisations that followed the CHMP’s scientific opinion before this time, and we ’re pleased that the commission has now recommended the blessing of the antibody combination.” It has also been conditionally recommended by WHO.
Expert insights. Personalized for you.
52 
Let's personalize your content